SUGIMURA Naomi, MIZOSHITA Tsutomu. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease. Dig Liver Dis. 2019
SUZUKI Taketo, MIZOSHITA Tsutomu. Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol. 2019
SUZUKI Taketo, MIZOSHITA Tsutomu. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-α inhibitor. JGH Open. 2019
MIZOSHITA Tsutomu. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (Baltimore). 2017
1998 - 2002 Nagoya City University Graduate School of Medical Sciences
1991 - 1997 Nagoya City University
Professional career (1):
博士(医学)
Work history (5):
2015/09 - 現在 Nagoya City University
2010/11 - 2015/08 Nagoya City University
2009/05 - 2010/10 Nagoya City University
2006/07 - 2009/04 Nagoya City University
2003/04 - 2006/06 Aichi Cancer Center, Research Institute
Association Membership(s) (6):
日本消化管学会
, JAPAN SOCIETY OF CLINICAL ONCOLOGY
, THE JAPANESE CANCER ASSOCIATION
, JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
, The Japanese Society of Gastroenterology